▼ bearish
Impact
PhasePhase 2 (RP completed); Phase 3 (PVRL on hold)
Time to marketUncertain. The PVRL program is in regulatory limbo after the SPA withdrawal and IND transfer request. The RP program has Fast Track designation but no Phase 2/3 trial has been confirmed as initiated. Even under optimistic scenarios, any potential approval is likely several years away.
ADX-2191 methotrexate (intravitreal formulation) Updated Nov 12
What to watch
Watch for the FDA's decision on Aldeyra's jurisdiction transfer request for ADX-2191's IND, which will determine which division oversees the PVRL program and what development path will be required. Also monitor whether the planned Phase 2/3 trial in retinitis pigmentosa ever initiates, as that would provide a future catalyst. The company's cash runway and the reproxalap appeal outcome are broader factors affecting ALDX's ability to fund ADX-2191 development.
Bull case
- ADX-2191 showed positive Phase 2 results in retinitis pigmentosa, with improvement from baseline in retinal function (Aldeyra press release, June 29, 2023).
- The FDA granted Fast Track designation for ADX-2191 in retinitis pigmentosa in August 2025, which can expedite development and review.
- The EMA granted Orphan Designation for ADX-2191 in both inherited retinal dystrophies (including RP) and primary large B-cell lymphomas (including PVRL) in 2025, providing market exclusivity benefits if approved.
Bear case
- ADX-2191 received a Complete Response Letter from the FDA in June 2023 for PVRL, with the agency citing lack of substantial evidence of effectiveness (BioWorld, June 21, 2023).
- On November 9, 2026, Aldeyra withdrew the Special Protocol Assessment agreement for ADX-2191 in PVRL and requested transfer of the IND to a different FDA division, creating significant regulatory uncertainty and putting the planned Phase 3 trial on hold indefinitely (SEC 8-K filed Nov 9, 2026).
- The PVRL program now faces potential delays, redesign, or discontinuation; any redesigned trial may be larger, longer, more costly, and harder to enroll given the rarity of the disease.